Abstract
Reliable estimation of the relationship between COVID-19 antibody levels at the time of exposure and the risk of infection is crucial to inform policy decisions on vaccination regimes. We fit a joint model of anti-spike IgG antibody decay and risk of COVID-19 infection to data from a randomized efficacy trial of the ChAdOx1 nCoV-19 vaccine. Our model improves upon previous analyses by accounting for measurement error, decay in antibody levels and variation between different individuals. We estimated correlates of protection, antibody decay, and vaccine efficacy waning. Increased anti-spike IgG antibody levels at the time of exposure correlate with increased vaccine-induced protection. We estimated vaccine efficacy against symptomatic COVID-19 infection of 88.1% (95% CrI: 77.2, 93.6) at day 35, waning to 60.4% (44.6, 71.0) at day 189 since the second dose. We report that longer intervals between the first and second vaccine dose give lasting increased protection, and observe lower efficacy in individuals aged ≥70 years from around 3 months after second dose. Our methods can be used in future vaccine trials to help inform the timings and priority of vaccine administration against novel diseases.
Competing Interest Statement
SF, AJP and MV are contributors to intellectual property licensed by Oxford University Innovation to AstraZeneca. AJP is Chair of the UK Department of Health and Social Care's (DHSC) Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in discussions on COVID-19 vaccines. The authors report no other conflicts of interest.
Clinical Trial
NCT04400838
Clinical Protocols
https://www.sciencedirect.com/science/article/pii/S0140673620326611?via%3Dihub
Funding Statement
The collection of the data used in this work was supported by the UK Research and Innovation (MC PC 19055), Engineering and Physical Sciences Research Council (EP/R013756/1), National Institute for Health Research (COV19 OxfordVacc-01), Coalition for Epidemic Preparedness Innovations (Outbreak Response To Novel Coronavirus (COVID-19)), National Institute for Health Research Oxford Biomedical Research Centre (BRC4 Vaccines Theme), Chinese Academy of Medical Sciences Innovation Fund for Medical Science, China (2018-I2M-2- 002), Thames Valley and South Midlands NIHR Clinical Research Network. DJP discloses support for the research of this work from the Engineering and Physical Sciences Research Council (EP/W523781/1). The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. AstraZeneca reviewed the final manuscript but the academic authors retained editorial control. Other funders had no role in study design, data collection and analysis, or decision to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The COV002 study was approved in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA), reference 21584/0428/001 0001, and the South-Central Berkshire Research Ethics Committee, reference 20/SC/0179. All participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Anonymized data will be made available via the Vivli platform https://vivli.org/. Source data for the figures are provided with this paper where possible.
